Bio-Path控股 BPTH 深 沪
已收盘 02-18 16:00:00 美东时间
0.21
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.21
- 总市值 150.36万
- 52周最高 7.6699
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.198
- 委 比 0.00%
- 总股本 716.02万
- 历史最高 1050.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.198
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
Bio-Path Holdings的CEO Peter Nielsen将于6月12日参加投资者论坛，介绍公司进展。该公司利用DNAbilize®技术开发抗癌和抗肥胖药物，其候选药物包括针对Grb2蛋白的prexigebersen和针对Bcl-2蛋白的BP1002，BP1003的IND申请即将提交。
06-09 11:00
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
Bio-Path Holdings, Inc. will host a live conference call on May 29, 2025, at 8:30 a.m. ET to discuss its business overview. The company, which leverages its proprietary DNAbilize® RNAi nanoparticle technology, is developing targeted nucleic acid drugs for cancer and obesity treatments. Key product candidates include prexigebersen and BP1002 for blood cancers and solid tumors, with additional studies for obesity and metabolic diseases in Type 2 diabetes patients.
05-22 20:30
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Conduit Pharmaceuticals (NASDAQ:CDT) stock increased by 27.4% to $0.16 during Monday's after-market session. The company's market cap stands at $15.0 million. TNF Pharmaceuticals (NASDAQ:TNFA) stock moved upwards by 18.82% to $2.02. The market value of their outstanding shares is at $4.7 mil...
2024-09-03 04:31
What Happened With Bio-Path Stock Today?
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares closed slightly higher Wednesday after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of prexigebersen...
2024-08-22 04:49
Traders Await Fed Minutes as US Equity Futures Post Narrow Gains Pre-Bell
08:51 AM EDT, 08/21/2024 (MT Newswires) -- US equity futures were cautiously higher before Wednesday's opening bell as traders looked ahead to minutes from the last Federal Reserve meeting for clues about future monetary policy. The Dow Jones Industrial Average futures gained 0.2%, S&P 500 futures i...
2024-08-21 20:51
Bio-Path Holdings Reports Tumor Regression in Early Trial for Solid Tumors; Shares Jump Pre-Bell
07:59 AM EDT, 08/21/2024 (MT Newswires) -- Bio-Path Holdings (BPTH) said Wednesday that a patient treated with a higher 90 mg/m2 dose in its Phase 1/1b clinical trial of BP1001-A for solid tumors showed tumor regression and stable disease. The company also noted "continued patient progress" in its P...
2024-08-21 19:59
